Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
about
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Intensive care unit and lung cancer: when should we intubate?Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.High proportion of rare and compound epidermal growth factor receptor mutations in an Australian population of non-squamous non-small-cell lung cancer.EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and PrognosisPemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR MutationsNew data on clinical decisions in NSCLC patients with uncommon EGFR mutations.EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature.Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.EGFR mutations in non-small cell lung cancer: an audit from West China Hospital.[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients.Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
P2860
Q33779181-D26FD160-B37A-4D1E-A7C3-3DA54B862446Q34376000-49A18220-3C0E-459E-9492-A2EBC208FBADQ34385995-004D06B1-2C01-4E65-A428-150CDCF47F25Q35257336-392B16DB-191F-44CE-AEC8-12FEA962C3DBQ36044399-0F18C068-3685-49FE-BB78-B149ACBE0822Q36187075-0F8B7528-AE5D-4C99-9B39-7E1533F481BDQ36215079-8116C618-3A63-423C-8C39-C4D7C592E45DQ36826056-4BFB9DB8-5D29-456A-B0C9-5DDACB98E190Q37344500-BA8D2916-88DB-4626-A88B-4E35C87C034CQ37697306-4E1DCF93-4EFE-43D2-8954-36C71E35DD07Q39129178-58EBAC80-CD9B-441E-B570-4FBF1CC29FE4Q39163315-DF57E779-88C4-4A8C-BB63-19B094796ECFQ39651867-25393C9E-00D8-40AE-8AEF-35C9FA6EB9E8Q41019653-ACD64F5D-033A-468F-A6EE-ADB06BAA7329Q47261717-3B7C7F0F-E4A6-476C-9EAE-800E4FAF0FAAQ47611571-E29FD9F3-B3ED-432B-A77D-3D486B17E6AEQ49379624-E89A5C6B-828B-4008-AD63-5B1FBFBA72C9Q50192132-01C3A2D0-4B40-4523-B15A-A736E4F4FE93Q51166938-18EF4F48-511F-44B2-85BE-53AD0839073CQ52332839-3C084618-BDDE-4F57-80FE-9B77D29187A4Q53094070-C9732361-2375-4411-B1E7-485138175682Q53843394-E30738E2-3421-4A7D-AFD0-84CA9381E160Q54339322-A2ED8937-E03B-4E88-BDB2-9A44D973E727Q54981628-08A4E5AD-6DA2-41ED-8A00-EB7100CE5C9DQ55181387-C5A5211B-BB81-4A7F-8537-870E82E447E6
P2860
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Rare and complex mutations of ...... th non-small cell lung cancer.
@en
Rare and complex mutations of ...... th non-small cell lung cancer.
@nl
type
label
Rare and complex mutations of ...... th non-small cell lung cancer.
@en
Rare and complex mutations of ...... th non-small cell lung cancer.
@nl
prefLabel
Rare and complex mutations of ...... th non-small cell lung cancer.
@en
Rare and complex mutations of ...... th non-small cell lung cancer.
@nl
P2093
P2860
P1476
Rare and complex mutations of ...... th non-small cell lung cancer.
@en
P2093
Bhumsuk Keam
Dae Seog Heo
Dong-Wan Kim
Doo Hyun Chung
Jeong-Ok Lee
Jin Hyun Park
Se-Hoon Lee
Tae Min Kim
P2860
P2888
P304
P356
10.1007/S10147-013-0602-1
P577
2013-08-06T00:00:00Z